{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-064358","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2022-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.921569+00:00","generated_at":"2026-06-27T02:08:40.541370+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Tyra Biosciences Q4 net loss $9.9M, cash $302.2M; IND filings on track","bullets":["Q4 2021 net loss $9.9M vs $3.7M; full-year net loss $26.3M vs $9.3M.","Cash and cash equivalents $302.2M at year-end 2021; no revenue reported.","IND for TYRA-300 (FGFR3) expected mid-2022; TYRA-200 (FGFR2) in H2 2022.","Appointed Allison Kemner as VP Clinical Sciences and Operations in Q4 2021.","Added to Russell 2000 Index in December 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-064358","json":"https://secwatch.observer/filing/0001193125-22-064358.json","markdown":"https://secwatch.observer/filing/0001193125-22-064358.md","text":"https://secwatch.observer/filing/0001193125-22-064358.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312522064358/0001193125-22-064358-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312522064358/d265803d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:08:40.541370+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}